Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage.

Wolenski FS, Shah P, Sano T, Shinozawa T, Bernard H, Gallacher MJ, Wyllie SD, Varrone G, Cicia LA, Carsillo ME, Fisher CD, Ottinger SE, Koenig E, Kirby PJ.

J Appl Toxicol. 2017 Mar;37(3):278-286. doi: 10.1002/jat.3358. Epub 2016 Jul 11.


The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.

Wolenski FS, Fisher CD, Sano T, Wyllie SD, Cicia LA, Gallacher MJ, Baker RA, Kirby PJ, Senn JJ.

Cell Death Discov. 2015 Oct 5;1:15034. doi: 10.1038/cddiscovery.2015.34. eCollection 2015.


Task appraisals, emotions, and performance goal orientation.

Fisher CD, Minbashian A, Beckmann N, Wood RE.

J Appl Psychol. 2013 Mar;98(2):364-73. doi: 10.1037/a0031260. Epub 2012 Dec 31.


Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.

Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ.

Drug Metab Dispos. 2012 Mar;40(3):450-60. doi: 10.1124/dmd.111.041095. Epub 2011 Nov 23.


Within-person relationships between mood and creativity.

To ML, Fisher CD, Ashkanasy NM, Rowe PA.

J Appl Psychol. 2012 May;97(3):599-612. doi: 10.1037/a0026097. Epub 2011 Oct 31.


Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ.

Drug Metab Dispos. 2011 Dec;39(12):2395-402. doi: 10.1124/dmd.111.041012. Epub 2011 Aug 30.


Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.

Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ.

Drug Metab Dispos. 2011 Oct;39(10):1954-60. doi: 10.1124/dmd.111.040592. Epub 2011 Jul 7.


Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ.

Drug Metab Dispos. 2010 Dec;38(12):2293-301. doi: 10.1124/dmd.110.035006. Epub 2010 Aug 30.


Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.

Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ.

Drug Metab Dispos. 2009 Oct;37(10):2087-94. doi: 10.1124/dmd.109.027466. Epub 2009 Aug 3.


Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, Cherrington NJ.

Eur J Pharmacol. 2009 Jun 24;613(1-3):119-27. doi: 10.1016/j.ejphar.2009.04.002. Epub 2009 Apr 7.


Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.

Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ.

Arch Toxicol. 2008 Dec;82(12):959-64. doi: 10.1007/s00204-008-0312-z. Epub 2008 May 17.


The Nrf2 activator oltipraz also activates the constitutive androstane receptor.

Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Huang W, Moore DD, Zhang Y, Klaassen CD, Cherrington NJ.

Drug Metab Dispos. 2008 Aug;36(8):1716-21. doi: 10.1124/dmd.108.020867. Epub 2008 May 12.


Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats.

Augustine LM, Fisher CD, Lickteig AJ, Aleksunes LM, Slitt AL, Cherrington NJ.

J Biochem Mol Toxicol. 2008 Mar-Apr;22(2):93-100. doi: 10.1002/jbt.20224.


Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis.

Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ.

J Biochem Mol Toxicol. 2007;21(4):216-20.


Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.

Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, Cherrington NJ.

Drug Metab Dispos. 2007 Oct;35(10):1970-8. Epub 2007 Jul 19.


Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2.

Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, Cherrington NJ.

Drug Metab Dispos. 2007 Jun;35(6):995-1000. Epub 2007 Mar 12.


Predictors of fear of hypoglycemia in adolescents with type 1 diabetes and their parents.

Gonder-Frederick LA, Fisher CD, Ritterband LM, Cox DJ, Hou L, DasGupta AA, Clarke WL.

Pediatr Diabetes. 2006 Aug;7(4):215-22.


Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto rats.

Slitt AL, Cherrington NJ, Fisher CD, Negishi M, Klaassen CD.

Drug Metab Dispos. 2006 Jul;34(7):1190-7. Epub 2006 Apr 18.


First-in-class pan caspase inhibitor developed for the treatment of liver disease.

Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, Ching B, Contreras P, Diaz JL, Fisher CD, Fritz LC, Gladstone P, Groessl T, Gu X, Herrmann J, Hirakawa BP, Hoglen NC, Jahangiri KG, Kalish VJ, Karanewsky DS, Kodandapani L, Krebs J, McQuiston J, Meduna SP, Nalley K, Robinson ED, Sayers RO, Sebring K, Spada AP, Ternansky RJ, Tomaselli KJ, Ullman BR, Valentino KL, Weeks S, Winn D, Wu JC, Yeo P, Zhang CZ.

J Med Chem. 2005 Nov 3;48(22):6779-82.


Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor.

Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC.

J Pharmacol Exp Ther. 2004 May;309(2):634-40. Epub 2004 Jan 23.


Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury.

Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, Contreras PC.

J Pharmacol Exp Ther. 2001 May;297(2):811-8.


Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy.

Miura M, Micca PL, Fisher CD, Gordon CR, Heinrichs JC, Slatkin DN.

Br J Radiol. 1998 Jul;71(847):773-81.


Response of the central nervous system to fractionated boron neutron capture irradiation: studies with borocaptate sodium.

Morris GM, Coderre JA, Hopewell JW, Rezvani M, Micca PL, Fisher CD.

Int J Radiat Biol. 1997 Feb;71(2):185-92.


Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine.

Morris GM, Coderre JA, Micca PL, Fisher CD, Capala J, Hopewell JW.

Br J Cancer. 1997;76(12):1623-9.


Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: biodistribution and toxicity in tumor-bearing mice.

Miura M, Micca PL, Fisher CD, Heinrichs JC, Donaldson JA, Finkel GC, Slatkin DN.

Int J Cancer. 1996 Sep 27;68(1):114-9.


Comparative assessment of single-dose and fractionated boron neutron capture therapy.

Coderre JA, Morris GM, Micca PL, Fisher CD, Ross GA.

Radiat Res. 1995 Dec;144(3):310-7. Erratum in: Radiat Res 1996 Mar;145(3):388.


Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex.

Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Liu HB.

Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):643-52.


Source of performance variance as a moderator of the job satisfaction-job performance relationship.

Fisher CD.

Int J Psychol. 1985 Jun;20(2):169-78. doi: 10.1080/00207598508247730.


Nutritional deficits exist before 2 months of age in some infants with cystic fibrosis identified by screening test.

Reardon MC, Hammond KB, Accurso FJ, Fisher CD, McCabe ER, Cotton EK, Bowman CM.

J Pediatr. 1984 Aug;105(2):271-4. No abstract available.


The other face of performance appraisal.

Fisher CD, Thomas J.

Hum Resour Manage. 1982 Spring;21(1):24-6. No abstract available.


Supplemental Content

Loading ...
Support Center